BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 17, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2001

View Archived Issues

Esperion Therapeutics begins phase IIa evaluation of LUV

Read More

Versicor and Biosearch Italia strengthen BIOCOR antiinfective alliance

Read More

Synapse's p97 delivers doxorubicin across BBB in preclinical study

Read More

Xcytrin clinical development program update

Read More

Microcide and J&J companies sign new and amend existing research agreement

Read More

Topical drug delivery technologies licensed by SkyePharma

Read More

Vertex updates progress during past year, provides outlook for this year

Read More

Corixa's RC-529 adjuvant enters phase III for HBV

Read More

Pharmacological characterization of S-18616, a highly potent and selective alpha2-AR agonist

Read More

Innogenetics' HCV therapeutic successfully completes phase I and moves towards phase II

Read More

LIPID substudy confirms beneficial effects of pravastatin in patients with unstable angina

Read More

Viventia Biotech's melanoma vaccine is safe and immunogenic

Read More

Anti-vWF MAb prevents thrombus deposition and neointima formation in guinea pigs

Read More

Protein Design Labs begins phase I/II trial with SMART antibody for Crohn's disease

Read More

Aurora Biosciences and GSK enter ion channel agreement

Read More

European marketing approval announced for noninvasive lung cancer diagnostic

Read More

Watson's Aslera scheduled for March FDA Arthritis Advisory Committee review

Read More

Proteomics-based RA diagnostics alliance formed by Roche and Millennium

Read More

UCB's nonsedating antihistamine approved in Germany

Read More

Authorization for pivotal trials of Generx sought in U.S.

Read More

Aixlie licenses cancer- and immune-related technologies from Ohio State

Read More

Successful phase I results for Enzo Biochem's HIV-1 gene medicine HGTV-43

Read More

Knoll patents compounds useful for depression and other disorders

Read More

Benzenesulfonamide-based inhibitors of ATP-sensitive K+ channels

Read More

DPP IV inhibitors synthesized at MCRF and their use

Read More

Sankyo's new HIV protease inhibitors show nanomolar activity

Read More

Japanese lab presents new series of TNF-alpha production inhibitors

Read More

Natural compounds for obesity with affinity for NPY receptors

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 17, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 16, 2025.
  • Child pushing away bowl of peanuts

    Vitesse finesse pays off: DBV wins in peanut allergy phase III

    BioWorld

    DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....

  • Handshake with tech background

    Harbour Biomed closes busy year with $1B+ BMS deal

    BioWorld
    Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing